KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Change in Account Payables (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Change in Account Payables for 8 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 252.63% to $3.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2025, up 605.77% year-over-year, with the annual reading at $5.0 million for FY2025, 605.77% up from the prior year.
  • Change in Account Payables hit $3.0 million in Q4 2025 for Vir Biotechnology, up from -$5.4 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $8.9 million in Q2 2025 to a low of -$7.5 million in Q3 2023.
  • Historically, Change in Account Payables has averaged $268350.0 across 5 years, with a median of -$99500.0 in 2023.
  • Biggest five-year swings in Change in Account Payables: tumbled 347.25% in 2021 and later surged 406.22% in 2025.
  • Year by year, Change in Account Payables stood at $788000.0 in 2021, then soared by 255.33% to $2.8 million in 2022, then fell by 6.18% to $2.6 million in 2023, then crashed by 173.7% to -$1.9 million in 2024, then skyrocketed by 252.63% to $3.0 million in 2025.
  • Business Quant data shows Change in Account Payables for VIR at $3.0 million in Q4 2025, -$5.4 million in Q3 2025, and $8.9 million in Q2 2025.